Baricitinib Reduces Signs, Symptoms of Cyclosporine-Resistant AD Baricitinib Reduces Signs, Symptoms of Cyclosporine-Resistant AD

Baricitinib 4 mg met the primary endpoint in a phase 3 study involving patients with AD who had failed or could not take cyclosporine.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Dermatology News Source Type: news